Search

Your search keyword '"Nijkamp, Wouter"' showing total 24 results

Search Constraints

Start Over You searched for: Author "Nijkamp, Wouter" Remove constraint Author: "Nijkamp, Wouter"
24 results on '"Nijkamp, Wouter"'

Search Results

1. Supplemental Figure S5 from Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance

2. Supplementary Table 2 from Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

3. Supplementary Table 1 from Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

4. Data from Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

5. Supplementary Figure 1 from Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

6. Supplementary Figure 3 from Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

7. Supplementary Figure 2 from Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

9. A large-scale RNAi screen in human cells identifies new components of the p53 pathway

10. Loss of ARID1A activates ANXA1, which serves as a predictive biomarker for trastuzumab resistance

11. Loss of ARID1A activates ANXA1, which serves as a predictive biomarker for trastuzumab resistance

12. Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance

13. SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer

14. SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer

18. MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling

19. A genome-wide RNAi screen in mouse embryonic stem cells identifies Mp1 as a key mediator of differentiation

20. NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease Outcome

21. Abstract A30: NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome

22. Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

24. A genome-wide RNAi screen in mouse embryonic stem cells identifies Mp1 as a key mediator of differentiation

Catalog

Books, media, physical & digital resources